European Organisation for Research and Treatment of Cancer - EORTC
eortc.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
351
Active
39
Phase 3
139
Total enrollment
110,935
Pipeline matrix
Showing 40 of 67 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| prednisone | — | — | — | — | 11 | ||
| vinblastine sulfate | — | — | — | — | 8 | ||
| bleomycin sulfate | — | — | — | — | — | 7 | |
| doxorubicin hydrochloride | — | — | — | — | 19 | ||
| vincristine sulfate | — | — | — | — | 11 | ||
| procarbazine hydrochloride | — | — | — | — | — | 4 | |
| mechlorethamine hydrochloride | — | — | — | — | — | 2 | |
| Local standard of Care | — | — | — | — | 2 | ||
| temozolomide | — | — | — | 17 | |||
| Lomustine | — | — | — | — | 5 | ||
| epirubicin hydrochloride | — | — | — | 4 | |||
| Pembrolizumab | — | — | — | — | 3 | ||
| ABVD regimen | — | — | — | — | — | 2 | |
| BEACOPP regimen | — | — | — | — | — | 2 | |
| DNA methylation analysis | — | — | — | — | — | 2 | |
| tamoxifen | — | — | — | — | — | 2 | |
| Vorasidenib | — | — | — | — | — | 1 | |
| Vorasidenib Placebo | — | — | — | — | — | 1 | |
| Preoperative chemotherapy | — | — | — | — | — | 1 | |
| Tebentafusp | — | — | — | — | — | 1 | |
| Duloxetine 60 MG | — | — | — | — | — | 1 | |
| Furosemide 40 mg | — | — | — | — | — | 1 | |
| iMAB | — | — | — | — | — | 1 | |
| cMAB | — | — | — | — | — | 1 | |
| Degarelix | — | — | — | — | — | 1 | |
| approved GnRH agonist | — | — | — | — | — | 1 | |
| Gilteritinib | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| Ra223 | — | — | — | — | — | 1 | |
| Enzalutamide | — | — | — | — | — | 1 | |
| Elacestrant | — | — | — | — | — | 1 | |
| Letrozole 2.5mg | — | — | — | — | — | 1 | |
| Anastrozole 1mg | — | — | — | — | — | 1 | |
| Exemestane 25 MG | — | — | — | — | — | 1 | |
| paclitaxel | — | — | — | 14 | |||
| cyclophosphamide | — | — | — | 18 | |||
| etoposide | — | — | — | — | 17 | ||
| carboplatin | — | — | — | — | 9 | ||
| dacarbazine | — | — | — | — | 3 |
27 more active programs hidden
Next readouts
- 1998-10-01
- 2000-05
- 2004-05
- 2018-09-05
- 2022-08-29
- 2023-01-13
- 2023-08-23
- 2023-08-28
- 2023-09-05
- 2023-10-24
Top conditions
- Breast Cancer28
- Leukemia25
- Lymphoma23
- Lung Cancer22
- Brain and Central Nervous System Tumors22
- Sarcoma20
- Colorectal Cancer20
- Prostate Cancer19
Frequently asked questions about European Organisation for Research and Treatment of Cancer - EORTC
- How many clinical trials does European Organisation for Research and Treatment of Cancer - EORTC have on ClinicalTrials.gov?
- European Organisation for Research and Treatment of Cancer - EORTC is listed as the lead sponsor on 351 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
- How many of European Organisation for Research and Treatment of Cancer - EORTC's trials are in Phase 3?
- 139 of European Organisation for Research and Treatment of Cancer - EORTC's trials are in Phase 3, spread across 67 active drug programs.
- What therapeutic areas does European Organisation for Research and Treatment of Cancer - EORTC focus on?
- European Organisation for Research and Treatment of Cancer - EORTC's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Leukemia, Lymphoma, Lung Cancer, Brain and Central Nervous System Tumors.
- When are European Organisation for Research and Treatment of Cancer - EORTC's next clinical trial readouts?
- European Organisation for Research and Treatment of Cancer - EORTC has 10 upcoming primary-completion readouts tracked here; the soonest is “Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma”, expected around 1998-10-01.